COMPARISON OF EFFICACY OF BARICITINIB VERSUS METHOTREXATE THERAPY IN THE TREATMENT OF SEVERE ALOPECIA AREATA
Main Article Content
Keywords
Alopecia areata, baricitinib, methotrexate.
Abstract
Background: Alopecia areata is an autoimmune and inflammatory disease of the hair follicle which has a detrimental effect on the quality of life. Due to the refractory nature of the disease, it presents a major challenge to the physicians. When choosing a systemic therapy for extensive and recalcitrant alopecia areata, methotrexate can be a reasonable option, though its use is limited by its limited efficacy and more adverse effects. In the recent times, Janus kinase (JAK) inhibitors have proven its efficacy in the treatment of severe alopecia areata. Materials and Methods: This randomized controlled trial was conducted in the department of Dermatology and Venereology, Bangabandhu Sheikh Mujib Medical University from the period of January 2023 till September 2024. About 84 patients of alopecia areata with more than 50% scalp involvement, patients with alopecia totalis and alopecia universalis were divided into two groups. Patients of group A were treated with oral baricitinib 4mg once daily and group B were treated with oral methotrexate 15mg once weekly with oral folic acid 5mg the following day for 6 months. Patients were assessed at baseline, 1st month, 3rd month and 6th month using Severity of Alopecia Tool (SALT) score. Results: The most common type of alopecia areata was patchy alopecia areata in both of the groups. Before treatment the SALT score was 71.1±19.62 in group A and 65.4±18.6 in group B. After 1 month, 3 month and 6 month the SALT score was 55.3±19.6, 37.9±23.3 and13.2±22.6 respectively in group A, whereas it was 64.6±19.3, 58.8±24.9 and 51.3±31.1 respectively in group B, which was statistically significant (p<0.001). Regarding percent change in SALT score, at month 6, SALT75 i.e. excellent response was seen in 19% patients of group A compared to 9.5% in group B; and SALT90 i.e. complete response was achieved in 57.1% patients in group A compared to none in group B. Conclusion: After 6 months of treatment, Baricitinib has proven its superiority over Methotrexate in terms of efficacy in the treatment of severe alopecia areata. Thus it can be recommended that, Baricitinib can be an excellent choice for patients with extensive disease, and further extended period research is necessary to assess its long term efficacy.
References
2. Hammerschmidt M & Mulinari Brenner F. Efficacy and safety of methotrexate in alopecia areata. Anais brasileiros de dermatologia 2014; 89: 729-734.
3. Mogul A, Corsi K, & McAuliffe, L. Baricitinib: The Second FDA-Approved JAK Inhibitor for the Treatment of Rheumatoid Arthritis. Annals of Pharmacotherapy (2019a);53(9): 947–953.
4. Numata T, Irisawa R, Mori M, Uchiyama M & Harada K. Baricitinib therapy for moderate to severe alopecia areata: A retrospective review of 95 Japanese patients. Acta Dermato Venereologica, 2024;104: adv18348.
5. Taylor S, Korman NJ, Tsai T, Shimomura Y, Feely M, Dutronc Y et al. Efficacy of Baricitinib in Patients with Various Degrees of Alopecia Areata Severity: Post-Hoc Analysis from BRAVE AA1 and BRAVE AA2. Dermatology and Therapy, 2023; 13(12): 3181–3191.
6. Khondker L, Sultana A & Khan MSI. The usefulness and wellbeing of Tofacitinib in the treatment of Alopecia Areata. Journal of Armed Forces Medical College, Bangladesh, 2022;18(1): 43–47.
7. Sedeh FB, Michaelsdóttir TE, Henning MAS, Jemec GBE, & Ibler KS. Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-analysis. Acta Dermato-Venereologica, 2023; 3: adv00855.
8. Lee HH, Gwillim E, Patel KR., Hua, T, Rastogi S, Ibler E & Silverberg JI. Epidemiology of alopecia areata, ophiasis, totalis, and universalis: A systematic review and meta-analysis. Journal of the American Academy of Dermatology, 2020; 82(3): 675–682.
9. Olamiju B, Friedmann A, King B. Treatment of severe alopecia areata with baricitinib. J Am Acad Dermatol. 2019;5(10):892–894.
10. Ali EN, Owais R, Sheikh A & Shaikh, AJ. Olumniant (Baricitinib) oral tablets: An insight into FDA-approved systemic treatment for Alopecia Areata. Annals of Medicine and Surgery, 2022; 80: 104157.
11. Freitas E, Guttman-Yassky E & Torres T. Baricitinib for the treatment of alopecia areata. Drugs, 2023; 83(9): 761–770.
12. Phan K, Ramachandran V & Sebaratnam DF. Methotrexate for alopecia areata: A systematic review and meta-analysis. Journal of the American Academy of Dermatology, 2018; 80(1): 120-127.e2.
13. Phan K, Sebaratnam DF. JAK inhibitors for alopecia areata: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2019; 33: 850–856
14. Browne R, Stewart L, Hywel C, Williams. Is methotrexate an effective and safe treatment for maintaining hair regrowth in people with alopecia totalis? A Critically Appraised Topic. British Journal of Dermatology, 2018; 179(3):609-614.
15. Rudnicka L, Arenbergerova M, Grimalt R, Ioannides D, Katoulis AC, Lazaridou E et al. European expert consensus statement on the systemic treatment of alopecia areata. Journal of the European Academy of Dermatology and Venereology, 2024; 38(4): 687–694.
16. Kabir S, Savitha B, Ananta K. Which is the Ideal JAK Inhibitor for Alopecia Areata – Baricitinib, Tofacitinib, Ritlecitinib or Ifidancitinib - Revisiting the Immunomechanisms of the JAK Pathway? Indian Dermatology Online Journal 2023; 14(4):465-474.
17. Olsen EA, Hordinsky MK, Price VH, Roberts JL, Shapiro J, Canfield D, et al. Alopecia areata investigational assessment guidelines–Part II. Journal of the American Academy of Dermatology 2004; 51(3): 440–447.
18. Kavak A, Yeşildal N, Parlak AH, Gökdemir G, Aydoǧan I, Anul H, et al., Alopecia areata in Turkey: Demographic and clinical features. Journal of the European Academy of Dermatology and Venereology, 2008; 22(8): 977–981.
19. Uzuncakmak T, Engin B, Serdaroglu S, Tuzun Y. Demographic and Clinical Features of 1,641 Patients with Alopecia Areata, Alopecia Totalis, and Alopecia Universalis: A Single-Center Retrospective Study. Skin Appendage Disorders,2021; 7(1): 8–12.
20. Zakaria A, Paul H, Islam M., & Islam A. Epidemiologic Profile of Alopecia areata – Study in a tertiary hospital in Bangladesh. Association of Physicians of Bangladesh, 2009; 20: 30-34.
21. King B, Ko J, Forman S, Ohyama M, Mesinkovska N, Yu G et al. Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study. Journal of the American Academy of Dermatology, 2021; 85(4): 847–853.
22. Senna M., Mostaghimi A, Ohyama M, Sinclair R., Dutronc Y, Wu WS et al. Long‐term efficacy and safety of baricitinib in patients with severe alopecia areata: 104‐week results from BRAVE‐AA1 and BRAVE‐AA2. Journal of the European Academy of Dermatology and Venereology, 2024; 38(3): 583–593
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Pranam Swapan Dash
Medical Officer, Department of Dermatology and Venereology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh.
Lubna Khondker
Associate Professor, Department of Dermatology and Venereology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh.
Md Alauddin Khan
Associate Professor, Department of Dermatology and Venereology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh.
Md. Shihab Talukder
MD Resident, Department of Dermatology and Venereology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh.
Sohely Jahan
Medical Officer, Department of Dermatology and Venereology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh.
Esrat khan Lubna
Consultant, Aurora Skin and Aesthetics, Dhaka, Bangladesh.